These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 23415508)

  • 41. Disclosing industry relationships--toward an improved federal research policy.
    Campbell EG; Zinner DE
    N Engl J Med; 2010 Aug; 363(7):604-6. PubMed ID: 20647185
    [No Abstract]   [Full Text] [Related]  

  • 42. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Institutional review boards (IRBs) and conflict of interest.
    Shamoo AE
    Account Res; 1999; 7(2-4):201-12. PubMed ID: 11658176
    [No Abstract]   [Full Text] [Related]  

  • 44. Conflict of interest issues pertinent to Veterans Affairs Medical Centers.
    Hanna J; Simiele E; Lawson DC; Tyler D
    J Vasc Surg; 2011 Sep; 54(3 Suppl):50S-4S. PubMed ID: 21872117
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ethics in evolution.
    Huston P
    CMAJ; 1996 Aug; 155(4):363. PubMed ID: 11654512
    [No Abstract]   [Full Text] [Related]  

  • 46. MPs call for removal of Health Canada's breast-implant panel members.
    Eggertson L
    CMAJ; 2005 Nov; 173(10):1144. PubMed ID: 16275959
    [No Abstract]   [Full Text] [Related]  

  • 47. Conflicts of interest in approvals of additives to food determined to be generally recognized as safe: out of balance.
    Neltner TG; Alger HM; O'Reilly JT; Krimsky S; Bero LA; Maffini MV
    JAMA Intern Med; 2013 Dec 9-23; 173(22):2032-6. PubMed ID: 23925593
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Panel that reviews gene tests in humans has no applications.
    Weiss R
    Washington Post; 1996 Feb; ():A3. PubMed ID: 11647100
    [No Abstract]   [Full Text] [Related]  

  • 49. FDA needs a more "nuanced" approach to advisers' conflicts of interest, researchers say.
    Dyer O
    BMJ; 2014 Sep; 349():g5665. PubMed ID: 25227397
    [No Abstract]   [Full Text] [Related]  

  • 50. NIH launches discussion of in utero gene therapy...and seeks to repair 'flaw' in review process.
    Wadman M
    Nature; 1998 Oct; 395(6701):420. PubMed ID: 9774086
    [No Abstract]   [Full Text] [Related]  

  • 51. Regulating biotechnology.
    McGarity TO
    Issues Sci Technol; 1985; 1(3):40-56. PubMed ID: 11649701
    [No Abstract]   [Full Text] [Related]  

  • 52. Role of the institutional animal care and use committee in monitoring research.
    Steneck NH
    Ethics Behav; 1997; 7(2):173-84. PubMed ID: 11655131
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Must an interest be a conflict?
    Lyles A
    Clin Ther; 2005 Mar; 27(3):344-5. PubMed ID: 15878388
    [No Abstract]   [Full Text] [Related]  

  • 54. Regulation of genetic engineering: less concern about Frankensteins but time for action on commercial production.
    Karny GM
    Univ Toledo Law Rev; 1981; 12(4):815-68. PubMed ID: 11649588
    [No Abstract]   [Full Text] [Related]  

  • 55. National, independent oversight: reinforcing the safety net for human subjects research.
    Mastroianni AC
    Account Res; 1999; 7(2-4):303-9. PubMed ID: 11658185
    [No Abstract]   [Full Text] [Related]  

  • 56. The role of academia and the research community in assisting the Food and Drug Administration to ensure U.S. drug safety.
    Lo Re V; Strom BL
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):818-25. PubMed ID: 17436357
    [TBL] [Abstract][Full Text] [Related]  

  • 57. RNA interference: a critical analysis of the regulatory and ethical issues encountered in the development of a novel therapy.
    McKnight R
    Albany Law J Sci Technol; 2004; 15(1):73-108. PubMed ID: 17340758
    [No Abstract]   [Full Text] [Related]  

  • 58. The concept of the IRB and bureaucratic reality: an exchange of letters.
    van Eys J; Levine RJ
    IRB; 1984; 6(4):8-10. PubMed ID: 11649563
    [No Abstract]   [Full Text] [Related]  

  • 59. What's wrong with money in science.
    Stossel T; Shaywitz D
    Washington Post; 2006 Jul; ():B3. PubMed ID: 16838447
    [No Abstract]   [Full Text] [Related]  

  • 60. Corporate responsibility for recombinant DNA activities.
    Berger BA
    Univ Toledo Law Rev; 1981; 12(4):913-24. PubMed ID: 11649592
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.